摘要
多发性骨髓瘤(multiple myeloma,MM)是一种克隆性浆细胞疾病,是全球第二常见的血液系统恶性肿瘤。21世纪以来,蛋白酶体抑制剂、免疫调节药物、单克隆抗体、双特异性抗体和嵌合抗原受体T细胞免疫治疗等各类新型治疗手段的应用,使MM患者的生存率得到提高[1]。但大部分MM患者在经历多药维持治疗后,仍会出现疾病的复发和进展。目前,MM尚不可治愈,迫切需要寻找新治疗靶点和探索新治疗模式。
Multiple myeloma(MM)is an incurable hematological malignancy characterized by the proliferation of clonal plasma cells.High relapse rate and acquired drug resistance remain key challenges for MM.Therefore,it is necessary to find new therapeutic targets and prognostic biomarkers for MM.Ferroptosis is a new type of iron-dependent programmed cell death,which can inhibit tumor.Recent studies have suggested that targeted induction of ferroptosis in MM cells through iron metabolism,lipid metabolism and other pathways can effectively inhibit the growth and proliferation of MM cells.In addition,ferroptosis-related genes are of great significance for the prognosis of MM.This review summarizes the progress of ferroptosis in MM.
作者
韩炯萍
方泽浩
封蔚莹
HAN Jiongping;FANG Zehao;FENG Weiying(School of Medicine,Shaoxing University,Shaoxing 312000,China;Department of Hematology,Shaoxing People's Hospital,Shaoxing 312000,China)
出处
《中国病理生理杂志》
CAS
CSCD
北大核心
2024年第4期748-754,共7页
Chinese Journal of Pathophysiology
基金
浙江省自然科学基金资助项目(No.LBY23H080002)
浙江省医药卫生科技计划项目(No.2023KY348)
浙江省卫生高层次人才-创新人才(浙卫办〔2022〕32号)。
关键词
多发性骨髓瘤
铁死亡
信号通路
multiple myeloma
ferroptosis
signaling pathway
